Biostatistical Analysis and Modeling of Behavioral Data

The contract calls for advanced statistical modeling of dose-effect and demand curve data to assess the abuse liability of drug candidates and produce comparative indices that enable meaningful evaluation across multiple compounds. This work requires sophisticated biostatistical techniques to analyze behavioral data, translating raw observational and experimental results into quantifiable metrics that inform regulatory and developmental decisions regarding substance risk profiles. The models must be robust, reproducible, and aligned with current scientific standards to support objective comparisons that guide prioritization and safety assessment of pharmaceutical candidates. This is an 8(a) Sole Source subcontract under NAICS code 541690, awarded by the FDA Office of Acquisition and Grant Services within the Department of Health and Human Services. The opportunity was posted on July 28, 2026, with a response deadline of August 4, 2026, indicating a tight turn-around for qualified firms to submit proposals. The work is performance-based and centers on high-level analytical capabilities, with no specified location for performance, suggesting flexibility in execution as long as deliverables meet technical requirements. The sole source designation implies the award is reserved for a small disadvantaged business certified under the 8(a) program, limiting competition to a single pre-qualified entity.